Guardant Health Announces COSMOS Study Results Published In Clinical Cancer Research; Largest Study To Date Evaluating Tissue-Free MRD Detection Shows 81% Sensitivity For Recurrence In Stage II Or Higher Colon Cancer
Portfolio Pulse from Benzinga Newsdesk
Guardant Health announced the results of the COSMOS study, published in Clinical Cancer Research. The study, the largest to date evaluating tissue-free MRD detection, shows 81% sensitivity for recurrence in stage II or higher colon cancer. The Guardant Reveal test demonstrated high sensitivity and specificity in predicting colorectal cancer recurrence, highlighting the clinical utility of ctDNA for rapid evaluation without prior tissue analysis.
August 07, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's COSMOS study results show 81% sensitivity for detecting colon cancer recurrence using the Guardant Reveal test. This highlights the clinical utility of ctDNA for rapid evaluation without prior tissue analysis.
The positive results from the COSMOS study, demonstrating high sensitivity and specificity of the Guardant Reveal test, are likely to boost investor confidence in Guardant Health's products. This could lead to a short-term increase in GH's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100